Performance of Medtronic Hybrid Closed-Loop Iterations, Results from a Randomized Trial in Adolescents with Type 1 Diabetes

Martin de Bock, Julie Dart, Michael Hancock, Grant Smith, Elizabeth A. Davis, Timothy W. Jones

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This study investigates the performance of an iteration of the Medtronic hybrid closed-loop (HCL) algorithm, which utilizes sensor glucose values non-adjunctively for bolus advice, recognizes sustained hyperglycemia, suggests insulin bolus correction, and includes more accommodative SmartGuard automode parameters that aim to improve function and usability. Adolescents aged 13-17 years with type 1 diabetes >1 year, glycated hemoglobin (HbA(1c)) 7.0%-10%, currently using Continuous Subcutaneous Insulin Infusion were randomized to the control Medtronic standard HCL algorithm or to the intervention Medtronic HCL with enhancements. Participants attended a 7-day and 7-night nonstructured camp setting. Twelve participants (mean age 15 years, seven males, five females, mean HbA(1c) 8.55%) completed the study. For the control group, time in target glucose sensor range (3.9-10mmol/L) was 63.68%+/- 10.74% at baseline and changed to 75.85%+/- 8.49% during the study (relative 19%). Time spent in

Original languageEnglish
Pages (from-to)693-697
Number of pages5
JournalDiabetes Technology & Therapeutics
Volume20
Issue number10
DOIs
Publication statusPublished - 11 Sep 2018

Cite this

@article{6f60210992834abe8959596486b801bd,
title = "Performance of Medtronic Hybrid Closed-Loop Iterations, Results from a Randomized Trial in Adolescents with Type 1 Diabetes",
abstract = "This study investigates the performance of an iteration of the Medtronic hybrid closed-loop (HCL) algorithm, which utilizes sensor glucose values non-adjunctively for bolus advice, recognizes sustained hyperglycemia, suggests insulin bolus correction, and includes more accommodative SmartGuard automode parameters that aim to improve function and usability. Adolescents aged 13-17 years with type 1 diabetes >1 year, glycated hemoglobin (HbA(1c)) 7.0{\%}-10{\%}, currently using Continuous Subcutaneous Insulin Infusion were randomized to the control Medtronic standard HCL algorithm or to the intervention Medtronic HCL with enhancements. Participants attended a 7-day and 7-night nonstructured camp setting. Twelve participants (mean age 15 years, seven males, five females, mean HbA(1c) 8.55{\%}) completed the study. For the control group, time in target glucose sensor range (3.9-10mmol/L) was 63.68{\%}+/- 10.74{\%} at baseline and changed to 75.85{\%}+/- 8.49{\%} during the study (relative 19{\%}). Time spent in",
keywords = "Type 1 diabetes, Closed loop, Pediatrics",
author = "{de Bock}, Martin and Julie Dart and Michael Hancock and Grant Smith and Davis, {Elizabeth A.} and Jones, {Timothy W.}",
year = "2018",
month = "9",
day = "11",
doi = "10.1089/dia.2018.0161",
language = "English",
volume = "20",
pages = "693--697",
journal = "Diabetes Technology & Therapeutics",
issn = "1557-8593",
publisher = "Mary Ann Liebert Inc",
number = "10",

}

Performance of Medtronic Hybrid Closed-Loop Iterations, Results from a Randomized Trial in Adolescents with Type 1 Diabetes. / de Bock, Martin; Dart, Julie; Hancock, Michael; Smith, Grant; Davis, Elizabeth A.; Jones, Timothy W.

In: Diabetes Technology & Therapeutics, Vol. 20, No. 10, 11.09.2018, p. 693-697.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Performance of Medtronic Hybrid Closed-Loop Iterations, Results from a Randomized Trial in Adolescents with Type 1 Diabetes

AU - de Bock, Martin

AU - Dart, Julie

AU - Hancock, Michael

AU - Smith, Grant

AU - Davis, Elizabeth A.

AU - Jones, Timothy W.

PY - 2018/9/11

Y1 - 2018/9/11

N2 - This study investigates the performance of an iteration of the Medtronic hybrid closed-loop (HCL) algorithm, which utilizes sensor glucose values non-adjunctively for bolus advice, recognizes sustained hyperglycemia, suggests insulin bolus correction, and includes more accommodative SmartGuard automode parameters that aim to improve function and usability. Adolescents aged 13-17 years with type 1 diabetes >1 year, glycated hemoglobin (HbA(1c)) 7.0%-10%, currently using Continuous Subcutaneous Insulin Infusion were randomized to the control Medtronic standard HCL algorithm or to the intervention Medtronic HCL with enhancements. Participants attended a 7-day and 7-night nonstructured camp setting. Twelve participants (mean age 15 years, seven males, five females, mean HbA(1c) 8.55%) completed the study. For the control group, time in target glucose sensor range (3.9-10mmol/L) was 63.68%+/- 10.74% at baseline and changed to 75.85%+/- 8.49% during the study (relative 19%). Time spent in

AB - This study investigates the performance of an iteration of the Medtronic hybrid closed-loop (HCL) algorithm, which utilizes sensor glucose values non-adjunctively for bolus advice, recognizes sustained hyperglycemia, suggests insulin bolus correction, and includes more accommodative SmartGuard automode parameters that aim to improve function and usability. Adolescents aged 13-17 years with type 1 diabetes >1 year, glycated hemoglobin (HbA(1c)) 7.0%-10%, currently using Continuous Subcutaneous Insulin Infusion were randomized to the control Medtronic standard HCL algorithm or to the intervention Medtronic HCL with enhancements. Participants attended a 7-day and 7-night nonstructured camp setting. Twelve participants (mean age 15 years, seven males, five females, mean HbA(1c) 8.55%) completed the study. For the control group, time in target glucose sensor range (3.9-10mmol/L) was 63.68%+/- 10.74% at baseline and changed to 75.85%+/- 8.49% during the study (relative 19%). Time spent in

KW - Type 1 diabetes

KW - Closed loop

KW - Pediatrics

U2 - 10.1089/dia.2018.0161

DO - 10.1089/dia.2018.0161

M3 - Article

VL - 20

SP - 693

EP - 697

JO - Diabetes Technology & Therapeutics

JF - Diabetes Technology & Therapeutics

SN - 1557-8593

IS - 10

ER -